염증성 근질환 환자의 생존율에 대한 예후 인자 연구 = Prognostic Factors Affecting Survival Rate in Inflammatory Myositis

다국어 초록 (Multilingual Abstract)

Objective: To assess the 10-year cumulative survival outcome of polymyositis (PM) and dermatomyositis (DM) as well as the factors associated with the the outcome. Methods: Eighty five patients with PM and twenty one patients with DM were diagnosed at our university medical center between 1997 and 2007. Thirty six patients with PM and 13 patients with DM were followed up until death or until the end of January, 2008. Gender, age, AST, ALT, CPK, LDH, ESR, CRP, aldolase, drugs of therapy, combined ILD, and cancer, and duration of remission after therapy were assessed as prognostic factors of death by the Kaplan-Meier curve and Cox regression model. Results: The respective 10-year survival rate for PM and DM was 80.8% (95% confidence interval (CI): 73.3∼87.2) and 55.9% (95% CI: 40.7∼71.1), respectively. The median survival for PM and DM was 11.3 years (95% CI: 9.8∼12.9) and 7.0 years (95% CI: 3.6∼10.5), respectively. Compared to DM patients, the subjects with PM had a 167.26 fold (95% CI: 7.59∼3683.19) combined ILD adjusted risk of mortality (p＜0.05) and no other individual factor reached significance as a predictor of death. However, cancer had a hazard ratio (HR) of 17.00 (95% CI: 1.06∼281.79) and 2.45 (95% CI: 0.78∼12.45) for death in the PM and DM group, respectively. Conclusion: According to an analysis of the survival and its prognostic factors in patients with PM and DM, ILD is a risk factor for mortality in PM and cancer was risk factor for mortality in both PM and DM.

참고문헌 (Reference)

1 김현숙, "염증성 근육병증에 동반된 폐침범의 임상적 특징" 대한류마티스학회 14 (14): 15-22, 2007

2 Rose AL, "polymyositis: a survey of 89 cases with particular reference to treatment and prognosis" 89 : 747-768, 1966

3 Amato AA, "Treatment of idiopathic inflammatory myopathies" 16 : 569-575, 2003

4 Choy EH, "Treatment of dermatomyositis and polymyositis" 41 : 7-13, 2002

5 Yoshida S, "The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue disease: a marker for a subset of polymyositis with interstitial pulmonary fibrosis" 26 : 604-611, 1983

6 Medsger TA, "The epidemiology of polymyositis" 48 : 715-723, 1970

7 Lee SH, "The clinical study on inflammatory myopathies" 2 : 42-51, 1995

8 Carpenter JR, "Survival in polymyositis; corticosteroids and risk factors" 4 : 207-214, 1977

9 Primack SL, "Radiologic manifestations of the systemic autoimmune diseases" 19 : 573-586, 1998

10 Benbassat J, "Prognostic factors in polymyositis/dermatomyositis" 28 : 249-255, 1985

11 DeVere R, "Polymyositis: its presentation, morbidity and mortality" 98 : 637-666, 1975

12 Selva-O'Callaghan A, "Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients" 14 : 534-542, 2005

13 Henrikkson KG, "Polymyositis treatment and prognosis; a study of 107 patients" 65 : 280-300, 1982

14 Bohan A, "Polymyositis and dermatomyositis (second of two parts)" 292 : 403-407, 1975

15 Bohan A, "Polymyositis and dermatomyositis (first of two parts)" 292 : 344-347, 1975

16 Veeraraghavan S, "Lung fibrosis: new classifications and therapy" 13 : 500-504, 2001

17 채정돈, "LG ENA Immunoblot 시약을 이용한 Extractable Nuclear Antigen 자가항체 검출" 대한진단검사의학회 22 (22): 34-41, 2002

18 Fathi M, "Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis" 63 : 297-301, 2004

19 Schnabel A, "Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment" 32 : 273-284, 2003

20 Grogan PM, "Inflammatory myopathies" 6 : 155-161, 2004

21 Medsger TA, "Factors affecting survivorship in polymyositis; a life-table study of 124 patients" 14 : 249-258, 1971

22 Tomoyuki F, "Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis" 32 : 58-64, 2005

23 Barnes BE, "Dermatomyositis and malignancy; a review of the literature" 84 : 68-76, 1976

24 Hochberg MC, "Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease" 11 : 663-665, 1984

25 Koh ET, "Adult onset polymyositis/dermatositis: clinical and laboratory features and treatment response in 75 patients" 52 : 857-861, 1993

26 Hochberg MC, "Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature" 15 : 168-178, 1986

27 Ogilvie CM, "A standardized breathholding technique for clinical measurement of the diffusing capacity of the lung for carbon monoxide" 36 : 1-7, 1957

28 Bohan A, "A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis" 56 : 255-286, 1977

29 Choi SJ, "A clinical analysis of 39 patients with dermatomyositis-polymyositis" 29 : 104-111, 1985

30 Kim SM, "A clinical analysis of 100 patients with dermatomyositis-polymyositis" 39 (39): 812-822, 1990